ARMONAIR DIGIHALER Drug Patent Profile

When do Armonair Digihaler patents expire, and what generic alternatives are available?

Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and eighty-nine patent family members in thirty-two countries.

The generic ingredient in ARMONAIR DIGIHALER is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-six suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Armonair Digihaler

A generic version of ARMONAIR DIGIHALER was approved as fluticasone propionate by ENCUBE on May 14^th, 2004.

Summary for ARMONAIR DIGIHALER

International Patents:	189
US Patents:	5
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARMONAIR DIGIHALER

US Patents and Regulatory Information for ARMONAIR DIGIHALER

ARMONAIR DIGIHALER is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-008	Apr 8, 2022		DISCN	Yes	No					Y
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-006	Feb 20, 2020		DISCN	Yes	No					Y
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-004	Feb 20, 2020		DISCN	Yes	No					Y
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-008	Apr 8, 2022		DISCN	Yes	No					Y
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-005	Feb 20, 2020		DISCN	Yes	No					Y
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-006	Feb 20, 2020		DISCN	Yes	No					Y

International Patents for ARMONAIR DIGIHALER

See the table below for patents covering ARMONAIR DIGIHALER around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2011254958
Brazil	112012029106
Canada	2799625
Canada	2887315
Canada	2936362
Canada	3019694

Supplementary Protection Certificates for ARMONAIR DIGIHALER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	18C1022	France		PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
1305329	SPC/GB08/026	United Kingdom		PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
1519731	92269	Luxembourg		PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1519731	132013902182575	Italy		PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
2506844	1890025-8	Sweden		PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117

Last updated: July 7, 2026

ARMONIAIR DIGIHALER (fluticasone furoate/umeclidinium/vilanterol) investment scenario and fundamentals analysis

Executive summary: ArmonAir Digihaler is a next-generation, add-on inhaled respiratory product built on fluticasone furoate–based inhaled corticosteroid therapy delivered via an electronic inhaler platform. Investment fundamentals hinge on (1) whether the product can expand beyond early adopters of digital inhaler systems, (2) sustained payer coverage in asthma and potential label expansion, and (3) how quickly competitors commoditize inhaled triple-therapy and ICS/LABA share through price pressure and formulary rotation. The patent estate and regulatory exclusivity profile, plus any Orange Book tethering to inhaler-device components, drive the risk-adjusted timeline for generic entry.

What is ARMONAIR DIGIHALER and what indication does it target?

Featured snippet answer: ArmonAir Digihaler is an inhaled asthma therapy delivered by a digital inhaler device, combining an inhaled corticosteroid with long-acting bronchodilator(s) in a fixed-dose regimen, aimed at improving adherence and inhalation technique.

Drug substance, dosing, and delivery approach

• Core therapeutic class: inhaled corticosteroid-based controller therapy for asthma
• Delivery system: electronic/digital inhaler intended to improve adherence and technique via sensing and user feedback

Where it fits clinically

• Target patient segment: asthma patients needing controller optimization and those struggling with technique/adherence
• Competitive positioning: sits against ICS/LABA and ICS/LABA/LAMA fixed-dose inhaled regimens, depending on payer and guideline adherence patterns

What patents protect ARMONAIR DIGIHALER in the US and how many are in-force?

Investment implication: A defensible patent estate lengthens the window for premium pricing, reduces generic revenue leakage, and raises the expected value of the platform economics behind electronic inhalers.

US patent estate and Orange Book tethering

• Key question investors price: whether patents cover not only the chemical composition and formulations, but also (a) device-delivery improvements and (b) dosing regimens or method-of-use claims that are hard for generics to design around.
• How to map the estate for diligence:
  1. Composition-of-matter patents covering active ingredients and salts/complexes (if claimed).
  2. Formulation patents covering particle engineering, spray/dry mix characteristics, and stability.
  3. Method-of-use patents for dosing schedules and asthma treatment.
  4. Device/inhalation-parameter patents if tethered claims exist for the digital inhaler mechanism.
  5. Process/manufacturing patents that can affect legal design-around timelines.

Featured snippet answer on durability

Featured snippet: The strength of ArmonAir Digihaler’s exclusivity outcome depends on the breadth of composition/formulation claims and whether device-connected claims exist that can delay FDA ANDA/BLA equivalents.

When does ARMONAIR DIGIHALER lose exclusivity and what are the key FDA exclusivity dates?

Featured snippet answer: The practical exclusivity clock is a combination of (1) patent expiration and (2) regulatory exclusivity such as new chemical entity/exclusivity for application type, plus device-related considerations if relevant.

How investors should structure the exclusivity timeline

Create a scenario tree with two “generic entry” milestones:

• ANDA/Biosimilar-style entry risk: when a generic combination inhaler can be approved and marketed (patent carve-outs, Paragraph IV filings, and settlement timing).
• Market access risk: when payers change formularies due to price pressure even before full legal exclusivity ends.

What to check in diligence

• Whether FDA listed exclusivity is tied to the formulation and combination components versus the device alone.
• Whether the product is protected by multiple “layers” (composition + formulation + method-of-use) that expire on different dates.

What is the Orange Book status of ARMONAIR DIGIHALER?

Featured snippet answer: Orange Book status determines whether investors should expect ANDA-related litigation, design-around risk, and how cleanly generics can substitute without infringing formulation or method-of-use claims.

How to interpret the listings for investment

• Number of Orange Book patents tied to the listed drug product.
• Patent types (composition vs formulation vs method-of-use) and whether they cover fixed-dose combination compatibility.
• Expiration distribution across years, which drives the probability of partial generic erosion at different times.

Are there Paragraph IV challenges or generic entry risks for ARMONAIR DIGIHALER?

Featured snippet answer: Generic entry risk is highest where (1) Orange Book has few blocking patents, (2) expiring patents cluster, and (3) settlements do not extend beyond the expected expiration window.

Investment scenario mechanics

• If Paragraph IV filings exist: expected to trigger Hatch-Waxman litigation and potential 180-day exclusivity for the first filer.
• If no Paragraph IV filings exist: risk moves to “at-expiration entry” where formulary and contracting decisions determine uptake speed.

What investors should model

• Litigation timing distribution: early, mid, late injunction probabilities.
• Expected net price erosion based on historical inhaler tender and rebate patterns following generic entry.

What patent litigation affects ARMONAIR DIGIHALER and how would it change valuation?

Featured snippet answer: The litigation catalyst is a function of patent count, claim breadth, and settlement posture, which determine whether generic launch is blocked, delayed, or permitted with carve-outs.

Valuation levers for litigation

• Injunction probability: depends on claim strength and whether the court sees likely infringement.
• Settlement length: can effectively extend commercial exclusivity beyond strict patent expiration.
• Work-sharing design-around: device and delivery improvements can narrow the infringement surface.

How does ARMONAIR DIGIHALER compare with competing inhaled asthma therapies?

Featured snippet answer: ArmonAir Digihaler competes in the asthma controller market against ICS/LABA and triple-therapy inhalers, with the digital inhaler platform as a differentiator in adherence and technique outcomes.

Competitive landscape by mechanism

• ICS/LABA fixed-dose: strong payer familiarity and established contracting.
• ICS/LABA/LAMA triple therapy: potentially higher symptom control, higher formulary hurdles.
• Digital inhaler platforms: differentiated by adherence support; price premium must be justified by outcomes and payer economics.

Where investors should focus

• Formulary wins: placement in preferred tiers and step-therapy exceptions.
• Adherence economics: whether digital feedback reduces exacerbations enough to offset premium pricing.

What are the commercial fundamentals for ARMONAIR DIGIHALER (demand, pricing, access)?

Featured snippet answer: The commercial profile hinges on whether the digital inhaler improves real-world persistence and whether payers treat those outcomes as cost-offsets.

Key commercial drivers

• Penetration velocity: adoption among guideline-based controller patients and those switching from prior inhalers.
• Persistence and switching rate: digital inhalers can reduce early discontinuation if benefits are communicated and supported.
• Net pricing: inhalers are rebate-sensitive; premium only holds if formulary leverage persists.
• Channel mix: specialty pharmacy vs institutional coverage and how rebates are structured.

Investment scenario design

Model three adoption curves:

• Base case: steady penetration with moderate payer uptake
• Bear case: payer pushes to cheaper non-digital incumbents; premium compresses
• Bull case: payer contracts based on adherence-linked endpoints

What manufacturing and device/IP barriers protect ARMONAIR DIGIHALER?

Featured snippet answer: Barriers can be both legal (composition/formulation/device claims) and operational (digital inhaler integration, calibration, and supply chain complexity).

Device and integration constraints

• Electronic inhalers typically require supply chain coordination for sensors, actuators, firmware, and validated subassemblies.
• Operational risk affects gross margin and supply reliability, which in inhalers can drive rapid competitive switches if stock-outs occur.

IP barriers tied to the device

• If patent claims cover device mechanics or method steps using digital feedback, generic substitutes may have higher design-around costs.

Is ARMONAIR DIGIHALER at risk from biosimilars or biologics displacement?

Featured snippet answer: Biosimilars are not a direct substitution risk for an inhaled controller. The displacement risk is biologics in severe asthma subsets where symptom control shifts to anti-inflammatory biologic regimens.

Investor relevance

• Scope: severe uncontrolled asthma is biologics-driven; controller inhalers face competition primarily through guideline step-up patterns and exacerbation reduction.
• What to model: whether digital inhaler adherence reduces exacerbations enough to delay biologic step-up.

What licensing deals or partnerships shape the upside for ARMONAIR DIGIHALER?

Featured snippet answer: Investment upside increases when partnerships improve distribution, payer negotiations, manufacturing scale, or co-development of inhaler-platform extensions.

Where partners typically matter

• Inhaler platform expansion: new fixed-dose combinations on the same device architecture.
• Geographic scaling: region-specific manufacturing or distribution agreements.
• Outcomes evidence partnerships: payers often demand real-world adherence and exacerbation proof.

What is the regulatory path for ARMONAIR DIGIHALER and how does it affect launch timing?

Featured snippet answer: Regulatory clearance determines label scope, then payers decide formulary adoption. Exclusivity is a function of the original approval pathway and any supplemental approvals tied to new strengths, regimens, or indications.

Potential label expansion scenarios investors model

• new asthma severity categories
• additional age groups
• refined dosing schedules

These expansions can extend commercial life even if core composition patents expire, depending on legal and regulatory exclusivity boundaries.

How strong is the patent estate for ARMONAIR DIGIHALER versus generic entry likelihood?

Featured snippet answer: Patent estate strength is high when multiple blocking patents cover distinct infringement surfaces: composition, formulation, method-of-use, and device-delivery steps. Generic likelihood rises when patents cluster near expiration or when device claims are narrow.

Scoring framework (investor-ready)

Use a 0 to 5 scoring rubric for:

1. Blocking patents count (Orange Book breadth)
2. Type diversity (composition vs formulation vs method/device)
3. Expiration dispersion
4. Settlement history (if any)
5. Design-around feasibility (practical, not theoretical)

Decision points

• High score supports premium pricing and multi-year revenue visibility.
• Low score shifts strategy toward faster contracting, lifecycle management, and platform monetization.

Key Takeaways

• ArmonAir Digihaler’s investment case is driven by a mix of legal exclusivity durability and commercial differentiation from a digital inhaler platform.
• The principal value-at-risk is payer-driven premium compression and accelerated generic substitution if the patent estate does not offer layered protection.
• The principal upside is payer adoption tied to adherence and exacerbation outcomes, supported by a multi-layer patent landscape and potentially blocking device-related claims.
• Fundamentals should be modeled around: exclusivity timeline, Orange Book breadth, Paragraph IV/settlement risk, and real-world persistence economics.

FAQs

1. How do Orange Book patent expirations translate into real-world generic launch dates for inhaled asthma drugs?
2. What claim types most often block ANDA entry for fixed-dose inhalers: composition, formulation, method-of-use, or device claims?
3. How does digital inhaler adoption affect payer contracting and net price in asthma controller therapies?
4. What market factors determine whether a digital inhaler retains premium pricing after competitor step-up therapies gain formulary share?
5. How should investors model settlement terms and 180-day exclusivity impact for potential generic filers in inhaled combinations?

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Hatch-Waxman Drug Patent and Exclusivity. U.S. Food and Drug Administration. https://www.fda.gov/drugs/